These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 24752083)

  • 1. Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment.
    Cassol E; Misra V; Dutta A; Morgello S; Gabuzda D
    AIDS; 2014 Jul; 28(11):1579-91. PubMed ID: 24752083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
    Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
    AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy.
    Anderson AM; Harezlak J; Bharti A; Mi D; Taylor MJ; Daar ES; Schifitto G; Zhong J; Alger JR; Brown MS; Singer EJ; Campbell TB; McMahon DD; Buchthal S; Cohen R; Yiannoutsos C; Letendre SL; Navia BA;
    J Acquir Immune Defic Syndr; 2015 May; 69(1):29-35. PubMed ID: 25622053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients.
    Dickens AM; Anthony DC; Deutsch R; Mielke MM; Claridge TD; Grant I; Franklin D; Rosario D; Marcotte T; Letendre S; McArthur JC; Haughey NJ
    AIDS; 2015 Mar; 29(5):559-69. PubMed ID: 25611149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in glutamate, arginine, and energy metabolism characterize cerebrospinal fluid and plasma metabolome of persons with HIV-associated dementia.
    Mastrangelo A; Scotti GM; Manteiga JG; Gisslén M; Price RW; Bestetti A; Turrini F; Caccia R; Gorelik L; Morelli MJ; Castagna A; Cinque P
    AIDS; 2024 Mar; 38(3):299-308. PubMed ID: 37905996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients.
    Thames AD; Briones MS; Magpantay LI; Martinez-Maza O; Singer EJ; Hinkin CH; Morgello S; Gelman BB; Moore DJ; Heizerling K; Levine AJ
    AIDS; 2015 Jul; 29(12):1483-91. PubMed ID: 26244388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.
    Cassol E; Misra V; Holman A; Kamat A; Morgello S; Gabuzda D
    BMC Infect Dis; 2013 May; 13():203. PubMed ID: 23641933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda.
    Abassi M; Morawski BM; Nakigozi G; Nakasujja N; Kong X; Meya DB; Robertson K; Gray R; Wawer MJ; Sacktor N; Boulware DR
    J Neurovirol; 2017 Jun; 23(3):369-375. PubMed ID: 27995575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND).
    Schrier RD; Hong S; Crescini M; Ellis R; Pérez-Santiago J; Spina C; Letendre S;
    PLoS One; 2015; 10(2):e0116526. PubMed ID: 25719800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
    Airoldi M; Bandera A; Trabattoni D; Tagliabue B; Arosio B; Soria A; Rainone V; Lapadula G; Annoni G; Clerici M; Gori A
    Clin Dev Immunol; 2012; 2012():467154. PubMed ID: 22489249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression.
    Cassol E; Misra V; Morgello S; Kirk GD; Mehta SH; Gabuzda D
    J Acquir Immune Defic Syndr; 2015 May; 69(1):18-28. PubMed ID: 25942456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
    Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
    Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S
    Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.
    McGuire JL; Gill AJ; Douglas SD; Kolson DL;
    J Neurovirol; 2015 Aug; 21(4):439-48. PubMed ID: 25776526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the aging process of cognitively healthy adults by analyzing cerebrospinal fluid metabolomics using liquid chromatography-tandem mass spectrometry.
    Liu FC; Cheng ML; Lo CJ; Hsu WC; Lin G; Lin HT
    BMC Geriatr; 2023 Apr; 23(1):217. PubMed ID: 37020298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia.
    Fazeli PL; Moore DJ; Franklin DR; Umlauf A; Heaton RK; Collier AC; Marra CM; Clifford DB; Gelman BB; Sacktor NC; Morgello S; Simpson DM; McCutchan JA; Grant I; Letendre SL
    Curr HIV Res; 2016; 14(4):324-30. PubMed ID: 26673902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
    Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
    AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.
    Rubin LH; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Kisakye A; Batte J; Mayanja R; Anok A; Lofgren SM; Boulware DR; Dastgheyb R; Reynolds SJ; Quinn TC; Gray RH; Wawer MJ; Sacktor N
    J Neurovirol; 2019 Dec; 25(6):800-813. PubMed ID: 31218522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid immune markers and HIV-associated neurocognitive impairments: A systematic review.
    Williams ME; Stein DJ; Joska JA; Naudé PJW
    J Neuroimmunol; 2021 Sep; 358():577649. PubMed ID: 34280844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients.
    Bai F; Iannuzzi F; Merlini E; Borghi L; Tincati C; Trunfio M; Bini T; Monforte AD; Marchetti G
    AIDS; 2017 Jan; 31(2):311-314. PubMed ID: 28005574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.